secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001104659-25-028529
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq panel grants Brainstorm Cell Therapeutics extension to June 30, 2025 to regain listing compliance
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted extension to June 30, 2025 to regain compliance with $35M minimum Market Value of Listed Securities.
- Company plans to meet $2.5M minimum stockholders' equity requirement as alternative to MVLS compliance.
- Extension conditioned on demonstrating compliance with Nasdaq Listing Rule 5550 and progress in capital raising.
- Company cannot assure success in raising capital or satisfying equity requirement by the extension date.
- Plan presented at February 25, 2025 hearing; capital raising activities are a key component.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925028529/0001104659-25-028529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925028529/tm2510584d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-028529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer